Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Pilot Study of PSMA-TRT Re-treatment Utilizing 225Ac-J591
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 19, 2023
A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2023
APEC1621C NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2023
Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 11, 2023
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 17, 2023
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 17, 2023
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 26, 2023
A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease (STOMP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 31, 2023
An open label, single arm study of the safety and antiretroviral activity of the combination of 2 long-acting broadly neutralizing antibodies plus an IL-15 superagonist complex in ART-treated adults living with HIV during analytical treatment interruption
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 31, 2023
Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 31, 2023